Aspen Pharmacare Holdings Limited (JSE:APN)

Market Cap	53.75B
Revenue (ttm)	45.53B
Net Income (ttm)	4.48B
Shares Out	444.21M
EPS (ttm)	10.08
PE Ratio	12.00
Forward PE	10.45
Dividend	3.59 (2.97%)
Ex-Dividend Date	Sep 18, 2024

Volume	2,988,552
Average Volume	1,322,733
Open	12,100
Previous Close	12,100
Day's Range	12,100 - 12,720
52-Week Range	10,575 - 25,296
Beta	0.42
RSI	62.93
Earnings Date	Sep 3, 2025

About Aspen Pharmacare Holdings

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counte...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1850
• Employees: 9,350
• Stock Exchange: Johannesburg Stock Exchange
• Ticker Symbol: APN

Financial Performance

In 2024, Aspen Pharmacare Holdings's revenue was 44.71 billion, an increase of 9.82% compared to the previous year's 40.71 billion. Earnings were 4.40 billion, a decrease of -15.76%.